Stock Quote
Biovail Corporation (BVF.N) (New York Stock Exchange)
$14.23
24 Nov 2009
-2.00%
$14.52
$14.40
663,200
$14.42
$14.15
$15.50
$7.53
0.80
1,479,711
BVF.N
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Squires, Douglas | Chairman of the Board | 4,574,620 |
| Wells, William | Chief Executive Officer, Director | 4,331,580 |
| Mulligan, Margaret | Chief Financial Officer, Senior Vice President | 347,086 |
Profile
Biovail Corporation (Biovail) is a specialty pharmaceutical company that applies advanced drug-delivery technologies to improve the clinical effectiveness of medicines. The Company is engaged in the formulation, clinical testing, registration, manufacture and commercialization of pharmaceutical... Full Description
Company Address
Biovail Corporation
7150 Mississauga Road
Mississauga ON L5N 8M5
P: +1905.2863000
F: +1905.6088118
7150 Mississauga Road
Mississauga ON L5N 8M5
P: +1905.2863000
F: +1905.6088118
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Watson Pharmaceuticals, Inc. | $37.05 | +1.50 |
| Alkermes, Inc. | $8.63 | -0.02 |
| Alkermes, Inc. | -- | -- |
| BVF.N | Industry | |
|---|---|---|
| P/E(TTM) | 10.28 | 3.60 |
| P/S(TTM) | 3.02 | 0.57 |
| ROI(TTM) | 14.37 | 1.86 |
| ROE(TTM) | 18.23 | 2.52 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | 0.50 |
| EPS Est. (Current Year) | 1.44 |
| Total Revenue | $212.52M |
| Net Income | $40.36M |
| EPS | $0.25 |
